Raymond James Financial
OTLK icon

Raymond James Financial’s Outlook Therapeutics OTLK Stock Holding History

Raymond James Financial’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$528K Buy
332,051
+305,000
+1,127% +$189K ﹤0.01% 4471
2026
Q1 		$5.57K Buy
+27,051
New +$11.7K ﹤0.01% 5270
2025
Q3 		– Sell
-2,851
Closed -$4.56K – 6201
2025
Q2 		$4.56K Buy
+2,851
New +$4.54K ﹤0.01% 6194

Other funds holding OTLK

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
GWM
Gilpin Wealth Management Denver, Colorado $145M AUM

Raymond James Financial's OTLK Position: Q2 2026 in Review

Raymond James Financial increased its Outlook Therapeutics (OTLK) stake by 1,127% in Q2 2026, buying an estimated $189K and bringing the position to 332,051 shares worth $528K. The position accounts for ﹤0.01% of the portfolio, ranked #4471.

Raymond James Financial first reported a position in OTLK in Q2 2025 and has held it in 3 quarters since. 68 funds tracked by Wall St. Rank hold OTLK as of Q2 2026.

  • Raymond James Financial held 332,051 shares of Outlook Therapeutics worth $528K as of Q2 2026.
  • Raymond James Financial bought 305,000 Outlook Therapeutics shares in Q2 2026, an estimated $189K.
  • Outlook Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #4471 holding.
  • Raymond James Financial first reported a position in Outlook Therapeutics in Q2 2025 and has held it in 3 quarters since.
  • 68 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.